Caladrius Biosciences Inc (CLBS.OQ)
CLBS.OQ on NASDAQ Stock Exchange Capital Market
4.59USD
1:30am IST
4.59USD
1:30am IST
Change (% chg)
$-0.04 (-0.86%)
$-0.04 (-0.86%)
Prev Close
$4.63
$4.63
Open
$4.61
$4.61
Day's High
$4.64
$4.64
Day's Low
$4.48
$4.48
Volume
4,396
4,396
Avg. Vol
17,340
17,340
52-wk High
$6.34
$6.34
52-wk Low
$2.65
$2.65
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | -0.84 | December | 24 Apr 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 0 | 0 | 0 | 0 |
| (2) OUTPERFORM | 2 | 2 | 2 | 2 |
| (3) HOLD | 0 | 0 | 0 | 0 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.00 | 2.00 | 2.00 | 2.00 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 1 | 0.00 | 0.00 | 0.00 | -- |
| Quarter Ending Sep-18 | 1 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-18 | 1 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-19 | 1 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | 1 | -0.84 | -0.84 | -0.84 | -- |
| Quarter Ending Sep-18 | 1 | -0.57 | -0.57 | -0.57 | -- |
| Year Ending Dec-18 | 1 | -2.74 | -2.74 | -2.74 | -- |
| Year Ending Dec-19 | 1 | -2.10 | -2.10 | -2.10 | -- |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Dec-17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Sep-17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Jun-17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Mar-17 | 9.50 | 7.92 | 1.58 | 16.60 |
| Quarter Ending Dec-16 | 7.05 | 10.18 | 3.13 | 44.34 |
| Earnings (per share) | ||||
| Quarter Ending Dec-17 | -0.73 | -0.41 | 0.32 | -43.84 |
| Quarter Ending Sep-17 | -0.77 | -0.38 | 0.39 | -50.97 |
| Quarter Ending Jun-17 | -0.96 | -0.22 | 0.74 | -77.08 |
| Quarter Ending Mar-17 | -0.72 | -1.12 | 0.40 | -55.56 |
| Quarter Ending Dec-16 | -0.80 | -0.73 | 0.06 | -8.18 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Jun-18 | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Quarter Ending Sep-18 | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-18 | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Year Ending Dec-19 | 0.00 | 0.00 | 0.00 | -- | 0.00 |
| Earnings (per share) | |||||
| Quarter Ending Jun-18 | -0.84 | -0.84 | -0.72 | -0.72 | -- |
| Quarter Ending Sep-18 | -0.57 | -0.57 | -0.71 | -0.71 | -- |
| Year Ending Dec-18 | -2.74 | -2.74 | -2.94 | -2.94 | -- |
| Year Ending Dec-19 | -2.10 | -2.10 | -- | -- | -- |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
| Earnings | ||||
| Quarter Ending Jun-18 | 0 | 0 | 0 | 1 |
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 1 |
| Year Ending Dec-19 | 0 | 0 | -- | -- |
Earnings vs. 
Estimates- BRIEF-Caladrius Biosciences Receives Sakigake Expedited Review Designation In Japan For CLBS12 For Treating Critical Limb Ischemia
- BRIEF-Caladrius Biosciences Q4 Loss Per Share $0.40 From Cont Ops
- BRIEF-Caladrius Biosciences Doses First Patient In Mid-Stage Critical Limb Ischemia Trial In Japan
- BRIEF-Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program
- BRIEF-Caladrius Biosciences Entered Common Stock Sales Agreement With H.C. Wainwright & Co